ANIP ANI Pharmaceuticals Corp: Enterprise Value to EBITDA Ratio
Risks of stagnation in niche generics are mitigated by stable demand for chronic medications for ANI Pharmaceuticals (ANIP). The company's EV/EBITDA metric visualizes these fluctuations, where the 7.38 level captures this indicator. Growth is driven by licensing partnerships and contract manufacturing. Logistics optimization and the diversification of raw material streams provide additional resilience, eliminating disruptions in the supply of finished medicines.
Comprehensive metric breakdowns and analytics for anipharmaceuticals.com (ANIP)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Debt to Equity ANI Pharmaceuticals|ANIP - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital ANI Pharmaceuticals, Inc.|ANIP - Company Aggregate Debts|Debt to Book Capitalization Ratio ANI Pharmaceuticals Corp|ANIP - Company Long-Term Indebtedness|Company Short-Term Debts ANI Pharmaceuticals|Quick Liquidity Indicator anipharmaceuticals.com
- financial results and valuation multiples details:
ANIP - Final Profit|Expected Profit ANI Pharmaceuticals|ANIP - Market Cap to Net Income|Forward P/E Multiple ANI Pharmaceuticals|ANIP - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple ANI Pharmaceuticals Corp|ANIP - Operating profit EBITDA|Earnings per share for the last twelve months ANI Pharmaceuticals|ANIP - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months anipharmaceuticals.com|ANIP - Net earnings per share growth this year|Earnings growth forecast for next year ANI Pharmaceuticals
Fundamental company analysis:ANIP (ANI Pharma)
Investors are assessing the potential of ANI Pharmaceuticals (ANIP) through the enterprise value to EBITDA ratio, which allows them to neutralize the impact of debt loads and tax regimes. The current EV/EBITDA multiple for ANI Pharmaceuticals (ANIP) reflects the efficiency of the Alimera Sciences integration and the growth in Cortrophin sales, helping to determine if the asset is undervalued against a backdrop of strong cash flow.
Competitor analysis for ANI Pharmaceuticals
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Group HLN|Kenvue Health (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|jyongbio.com - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company) - EV/EBITDA Multiple|Company Value to EBITDA Alvotech Biopharmaceuticals ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia Corporation (LQDA)|GLPG (glpg.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple MNKD (MannKind)|EV/EBITDA Multiple Amphastar Pharmaceuticals Inc AMPH|PCRX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SPRY (ARS Corp) - Enterprise Value to Operating Income Before Depreciation|TBPH: EV/EBITDA Multiple|AQST - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio SCPH|TECX: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tonix Pharmaceuticals Inc. (TNXP)|SXTC: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple EPRX (Eupraxia Pharmaceuticals Inc.)|Business Value to Operating Income Before Depreciation BHST|eXoZymes - EV/EBITDA Multiple|ORMP - EV/EBITDA Multiple|enterabio.com (ENTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MindWalk Therapeutics - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ABVC BioPharma|Enterprise Value to EBITDA Ratio cumberlandpharma.com (CPIX)|EV/EBITDA Multiple QNTM|EV/EBITDA Multiple FibroGen Inc (FGEN)|EV/EBITDA Multiple TELO (Telomir Pharma)|RANI - Enterprise Value to EBITDA Ratio|Synergy CHC Corporation - EV/EBITDA Multiple|Company Value to EBITDA Rallybio Corporation|LEXX (lexariabioscience.com) - Enterprise Value to EBITDA Ratio|Pulmatrix Inc (PULM) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio PTHL|APM (Aptorum) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple LYRA|Total Company Value to Operating Income Before Depreciation Ratio impactbiomedinc.com|EV/EBITDA Multiple TNFA (TNF Pharmaceuticals, Inc.)|YCBD - Enterprise Value to EBITDA Ratio|PainReform Limited - EV/EBITDA Multiple|CYTO - EV/EBITDA Multiple|Lipella Pharmaceuticals (LIPO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|OPTN (optinose.com) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pieris Pharmaceuticals, Inc.|Procaps Group (PROC) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple PTPI|EV/EBITDA Multiple Qilian International Corp (QLI)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Acelyrin, Inc. SLRN|TFFP: Enterprise Value to Operating Income Before Depreciation
